Completed PHASE3 INTERVENTIONAL 2-arm NCT01493947

CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study (ATTRACT)

Efficacy and Safety of CD5024 1% Cream Versus Metronidazole 0.75% Cream in Subjects With Papulopustular Rosacea Over 16 Weeks Treatment, Followed by a 36-week Extension Period.

Sponsor: Galderma R&D

Conditions Papulopustular Rosacea

Interventions Ivermectin 1% cream Metronidazole 0.75% cream

Updated 8 times since 2017 Last updated: Sep 22, 2015 Started: Apr 30, 2012 Primary completion: Dec 31, 2013 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Papulopustular Rosacea, this trial is completed. The trial is conducted by Galderma R&D and has accumulated 8 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jan 2021 — Dec 2022 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Apr 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Galderma R&D

Data source: Galderma R&D

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Augsburg, Germany , Berkshire, United Kingdom , Berlin, Germany , Bexhill-on-Sea, United Kingdom , Bialystok, Poland , Bonn, Germany , Bordeaux, France , Brasov, Romania , Brest, France , Bucharest, Romania and 47 more locations